'New drug approval process' presentation slideshows

Michael A. Swit, Esq. Vice President

Michael A. Swit, Esq. Vice President. FDA Regulatory Considerations for Life Sciences Companies Swedish-American Chamber of Commerce E-Days Life Sciences Program April 9, 2008 San Diego, California. Standard Disclaimers.

413 views • 30 slides

FDA Legal & Regulatory Considerations for Biomedical Startups

FDA Legal & Regulatory Considerations for Biomedical Startups. Tech Coast Angels San Diego, California March 7, 2003. FDA Counsel .com. Michael A. Swit, Esq. Michael A. Swit, Esq. Law Offices of Michael A. Swit 539 Samuel Ct. Encinitas, CA 92024 760-815-4762; fax: 760-454-2979

434 views • 25 slides

New Drug Approval Process

668 views • 16 slides

Overview of FDA's Regulatory Compliance Agenda

Overview of FDA's Regulatory Compliance Agenda. Daniel Meron, Esq. General Counsel Department of Health and Human Services August 22, 2007. Topics. Regulation of Drug Compounding Enforcement Regarding Unapproved Drugs Off-Label Promotion Investigations and Enforcement Preemption.

203 views • 10 slides